Alzyn is a researched-based development stage company pursuing a unique approach to retard the progress of Alzheimer's Disease employing a combination of well-characterized active ingredients.

AD is a Hydra, with several conditions combining to advance the disease. Current therapies may attack one of the Hydra’s heads but ignore the others, resulting in a continued decline in the patients condition.

Our leading AD researcher and her team completed extensive work on the effects of four well-characterized ingredients individually and various combinations..

Her team established that a combination of the four compounds had a marked ability to retard the overproduction of the beta-amyloid plaques, believed by most experts to be the cause of AD .

They also observed significant reduction in levels of the beta amyloid peptides, as well as pro-inflammatory proteins and reactive oxygen species which are believed to drive the cascading symptoms of AD as it progresses.

Delivery of the compounds in combination also resulted in an increased expression of anti-apoptotic proteins and anti-oxidative enzymes which are part of the brain’s defenses against the disease.

Alzyn is currently building upon those learnings to develop a product that can safely and effectively deliver therapeutic doses across the blood brain barrier.